The largest database of trusted experimental protocols

Amoxicillin clavulanic acid

Manufactured by Laborclin
Sourced in Brazil

Amoxicillin + Clavulanic acid is a combination of two antibacterial agents. Amoxicillin is a penicillin-type antibiotic, and Clavulanic acid is a beta-lactamase inhibitor. This combination is used to treat a variety of bacterial infections.

Automatically generated - may contain errors

2 protocols using amoxicillin clavulanic acid

1

Antibiotic Susceptibility of Bacteria after aPDT

Check if the same lab product or an alternative is used in the 5 most similar protocols
To test if a dose of aPDT could promote damage to bacteria envelope and facilitate antibiotic penetration into the cell, an antibiotic resistance/susceptibility test was performed using antibiotic discs of Ampicillin – 10μg, Amoxicillin + Clavulanic acid – 20μg, Clindamycin – 2μg and Ertromycin 15μg (Laborclin, Pinhais Brazil) and MIC50 test, based on CSLI [30 ] and EUCAST reference values [31 (link)]. For combined therapy, aPDT was applied with parameters of lethal and sublethal dose, before antibiotic challenge. For this experiment ATCC strain was used as recommended by CSLI and EUCAST tests.
+ Open protocol
+ Expand
2

Antibiotic Resistance Profiling of Isolates

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genotypic and phenotypic resistance profiles of isolates were determined using a PCR approach (ARGs and integrases molecular detection) and the Kirby and Bauer method (Bauer et al., 1966 (link)), respectively. The PCR technique was applied to identify the presence of genes encoding β-lactamases (blaTEM, blaVIM, blaIMP, blaCTX, blaSHV, and blaKPC) as previously described by Alves et al. (2014) (link) (Supplementary Table S2). To determine susceptibility profiles, 16 antibiotics were tested by the Kirby and Bauer method on Mueller-Hinton agar medium (Kasvi) in duplicate. The isolates were incubated for 16–24 h at 37°C. The antibiotics used were amoxicillin (10 μg), amoxicillin/clavulanic acid (20 μg/10 μg), ampicillin (10 μg), aztreonam (30 μg), cefepime (30 μg), ceftazidime (30 μg), cefotaxime (30 μg), cephalothin (30 μg), ciprofloxacin (5 μg), chloramphenicol (30 μg), gentamicin (10 μg), imipenem (10 μg), kanamycin (30 μg), nalidixic acid (30 μg), sulfamethoxazole/trimethoprim (25 μg) and tetracycline (30 μg) (Laborclin, Brazil). The strain Escherichia coli ATCC 25922 was used as a control. The mean and standard deviation of inhibition halo values of duplicate were compared to those standardized by the Clinical and Laboratory Standards Institute (CLSI) to classify the strains as susceptible, intermediate or resistant (CLSI, 2017 ).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!